ArticleGastroenterology report2026
Immune-based personalized elimination diet for the treatment of irritable bowel syndrome: a double-blind randomized sham-controlled study.
Article in Gastroenterology report, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dietary interventions and multiple food-item restrictions are challenging for patients with irritable bowel syndrome (IBS), and associated with inadequate adherence. We aimed to examine the efficacy of an individualized-selective dietary intervention, based on Leukocyte activation to food-components (i.e. Alcat-guided diet) in IBS. Methods: A randomized, double-blind, sham-controlled trial allocated IBS patients at Sheba Medical Center (Ramat Gan, Israel) between 5 August 2020 and 11 April 2022 to either an Alcat-guided or a sham-balanced diet for 8-week treatment. The primary outcome was a 50-point reduction on the IBS-symptom severity scale (IBS-SSS). The rates of improvement in the IBS Global Improvement Scale (IBS-GIS) and positive response (yes/no) were defined as secondary and exploratory outcomes, respectively. Results: A total of 68 patients with IBS-D/M (44/24) were enrolled. Baseline characteristics were comparable between groups except for a higher median IBS-SSS score in the Alcat group compared with controls [390 (305-435) vs 330 (240-390), Conclusion: Immune-based personalized-diet was more efficient than sham-based diet for reducing symptoms in IBS patients, and may serve as a safe treatment option in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.